Neurocrine Biosciences
NBIX
#1235
Rank
C$20.67 B
Marketcap
$204.25
Share price
2.19%
Change (1 day)
14.85%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - P/B ratio

P/B ratio as of January 2025 : 5.25

According to Neurocrine Biosciences 's latest financial reports the company has a price-to-book ratio of 6.36789.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Neurocrine Biosciences - P/B ratio (from 2001 to 2024)

P/B ratio by year

Year P/B ratio Change
2024-12-315.19-10.47%
2023-12-315.80-13.73%
2022-12-316.7214.33%
2021-12-315.88-26.05%
2020-12-317.95-48.94%
2019-12-3115.615.47%
2018-12-3113.5-26.91%
2017-12-3118.572.81%
2016-12-3110.7-7.13%
2015-12-3111.540.46%
2014-12-318.1956.68%
2013-12-315.2262.26%
2012-12-313.22-58.81%
2011-12-317.82-63.93%
2010-12-3121.7-28.38%
2009-12-3130.3801%
2008-12-313.36129.43%
2007-12-311.4616.64%
2006-12-311.26-78.98%
2005-12-315.9730.56%
2004-12-314.57-7.13%
2003-12-314.92-21.13%
2002-12-316.24

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
4.39-16.35%๐Ÿ‡บ๐Ÿ‡ธ USA
1.76-66.44%๐Ÿ‡ฌ๐Ÿ‡ง UK
-3.42-165.08%๐Ÿ‡บ๐Ÿ‡ธ USA
46.9 792.50%๐Ÿ‡บ๐Ÿ‡ธ USA
49.9 849.35%๐Ÿ‡บ๐Ÿ‡ธ USA
1.61-69.29%๐Ÿ‡บ๐Ÿ‡ธ USA
2.73-48.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0229-100.44%๐Ÿ‡บ๐Ÿ‡ธ USA